Drugs Made In America Acquisition Corp. (DMAAR) Stock Price, Financials & Summary

Price chart

Sep 25Sep 30Oct 6Oct 9Oct 14Oct 21Oct 26Oct 29

Key dataOct 29, 2026

Open$0.11

From 52W high−50.50%

Volume12431.00

Market cap$2.50M

P/E (TTM)0.6x

P/S (TTM)—

Div yield—

Key dataOct 29, 2026

Open

$0.11

From 52W high

−50.50%

Volume

12431.00

Market cap

$2.50M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.3x

P/E (TTM)

0.6x

RSI (14)

46.1

MomentumView details →

1D Return

+14.03%

YTD Return

−41.86%

SummaryUpdated Jun 1, 2026

Drugs Made In America Acquisition Corp. (NASDAQ:DMAAU) is a special purpose acquisition company (SPAC) founded on May 23, 2024, and headquartered in Fort Lauderdale, Florida. The company went public on January 27, 2025, as a blank check company designed to identify and merge with or acquire businesses in the pharmaceutical and healthcare sectors. As a newly formed entity, DMAAU operates as an investment vehicle seeking to complete a business combination with one or more target companies, with a particular focus on businesses involved in domestic pharmaceutical manufacturing and related healthcare services.

Ask drillr about Drugs Made In America Acquisition Corp. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

0.6x

EV/EBITDA

−1.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

4.42%

ROA (TTM)

4.15%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−99.85%

FCF YoY

+46.96%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+439.29%

EBITDA YoY

—

MomentumView details →

1D Return

+14.03%

YTD Return

−41.86%

1Y Return

−41.45%

RSI (14)

46.1

vs 50D SMA

−13.07%

vs 200D SMA

−5.93%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

0.02x

Quick Ratio

0.02x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

6.09M

Op. CF (TTM)

−323129.00

Latest newsMore news →

Drugs Made In America Acquisition Corp. entered into an Amended and Restated Definitive Merger Agreement with Power Analytics Global Corp, fixing a closing valuation of US$2.85 billion for the merger.46d ago

Similar companies

Spark I Acquisition Corp. WarrantSPKLW FIGX Capital Acquisition Corp. WarrantFIGXW Cal Redwood Acquisition Corp. RightCRAQR Long Table Growth Corp. WarrantsLTGRW RMG ML Sports HoldingsSHOTR Columbus Acquisition Corp RightsCOLAR Find similar companies →

Latest newsMore news →